Mirtazapina Psidep 30 Mg Comprimidos Revestidos (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Psidep 30 Mg Comprimidos Revestidos, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a 30 mg film‑coated tablet for oral use. It is prescribed for major depressive disorder in adult patients, helping to improve mood, sleep and appetite, and is manufactured under EU quality standards.

GNH USA supplies Mirtazapina Psidep 30 Mg Comprimidos Revestidos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is an antidepressant that acts on noradrenergic and serotonergic pathways, primarily indicated for the following conditions:

- Major depressive disorder: reduces depressive symptoms and improves overall functioning in adults. - Treatment‑resistant depression: may be added when first‑line antidepressants are insufficient. - Depression in the elderly: helps with mood, sleep and appetite disturbances common in older patients.

Mirtazapine may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Sedation: drowsiness, especially at treatment initiation. - Increased appetite/weight gain: notable in many patients. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Dizziness: orthostatic light‑headedness. - Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Seizures: rare but possible convulsive events. - Severe neutropenia: marked decrease in neutrophil count. - Hepatotoxicity: liver enzyme elevations or injury. - Suicidal ideation: emergence of suicidal thoughts, particularly early in therapy. - Serotonin syndrome: when combined with other serotonergic agents.

When prescribing mirtazapine, clinicians should consider several safety precautions to minimize risk.

- Assess hepatic function: adjust use in patients with severe liver impairment. - Monitor for suicidal thoughts: especially during the first weeks of treatment. - Caution in elderly: increased risk of sedation, falls and orthostatic hypotension. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CYP2D6 inhibitors (e.g., fluoxetine): increased mirtazapine plasma levels. - Other CNS depressants (e.g., alcohol, benzodiazepines): enhanced sedation. - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - QT‑prolonging drugs: additive cardiac risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine): reduced efficacy. - Anticholinergic drugs: additive dry‑mouth effects. - Antihistamines: increased sedation. - Lithium: monitor lithium serum concentrations. - Warfarin: monitor INR for possible anticoagulation changes.